eprintid: 10118088
rev_number: 25
eprint_status: archive
userid: 608
dir: disk0/10/11/80/88
datestamp: 2021-01-07 11:13:44
lastmod: 2022-02-25 16:35:01
status_changed: 2021-01-07 11:13:44
type: article
metadata_visibility: show
creators_name: Stock, CJW
creators_name: Hoyles, RK
creators_name: Daccord, C
creators_name: Kokosi, M
creators_name: Visca, D
creators_name: De Lauretis, A
creators_name: Alfieri, V
creators_name: Kouranos, V
creators_name: Margaritopoulos, G
creators_name: George, PM
creators_name: Molyneaux, PL
creators_name: Chua, F
creators_name: Maher, TM
creators_name: Abraham, DJ
creators_name: Ong, V
creators_name: Donovan, J
creators_name: Sestini, P
creators_name: Denton, CP
creators_name: Wells, AU
creators_name: Renzoni, EA
title: Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G90
keywords: CYFRA 21-1, Krebs von den Lungen-6, MUC1 allele, biomarker, disease progression, systemic sclerosis-associated interstitial lung disease
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: BACKGROUND AND OBJECTIVE: The course of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is highly variable, and accurate prognostic markers are needed. KL-6 is a mucin-like glycoprotein (MUC1) expressed by type II pneumocytes, while CYFRA 21-1 is expressed by alveolar and bronchiolar epithelial cells. Both are released into the blood from cell injury. METHODS: Serum KL-6 and CYFRA 21-1 levels were measured in a retrospective (n = 189) and a prospective (n = 118) cohort of SSc patients. Genotyping of MUC1 rs4072037 was performed. Linear mixed-effect models were used to evaluate the relationship with change in lung function parameters over time, while association with survival was evaluated with Cox proportional hazard analysis. RESULTS: In both cohorts, KL-6 and CYFRA 21-1 were highest in patients with lung involvement, and in patients with extensive rather than limited ILD. KL-6 was higher in patients carrying the MUC1 rs4072037 G allele in both cohorts. In patients with SSc-ILD, serum KL-6, but not CYFRA 21-1, was significantly associated with DLCO decline in both cohorts (P = 0.001 and P = 0.004, respectively), and with FVC decline in the retrospective cohort (P = 0.005), but not the prospective cohort. When combining the cohorts and subgrouping by severity (median CPI = 45.97), KL-6 remained predictive of decline in DLCO in both milder (P = 0.007) and more severe disease (P = 0.02) on multivariable analysis correcting for age, gender, ethnicity, smoking history and MUC1 allele carriage. CONCLUSION: Our results suggest serum KL-6 predicts decline in lung function in SSc, suggesting its clinical utility in risk stratification for progressive SSc-ILD.
date: 2021-05
date_type: published
official_url: http://dx.doi.org/10.1111/resp.13988
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1839436
doi: 10.1111/resp.13988
lyricists_name: Abraham, David
lyricists_name: Denton, Christopher
lyricists_name: Ong, Voon
lyricists_id: DJABR26
lyricists_id: CPDEN87
lyricists_id: VONGX45
actors_name: Denton, Christopher
actors_id: CPDEN87
actors_role: owner
full_text_status: public
publication: Respirology
volume: 26
number: 5
pagerange: 461-468
event_location: Australia
citation:        Stock, CJW;    Hoyles, RK;    Daccord, C;    Kokosi, M;    Visca, D;    De Lauretis, A;    Alfieri, V;                                                     ... Renzoni, EA; + view all <#>        Stock, CJW;  Hoyles, RK;  Daccord, C;  Kokosi, M;  Visca, D;  De Lauretis, A;  Alfieri, V;  Kouranos, V;  Margaritopoulos, G;  George, PM;  Molyneaux, PL;  Chua, F;  Maher, TM;  Abraham, DJ;  Ong, V;  Donovan, J;  Sestini, P;  Denton, CP;  Wells, AU;  Renzoni, EA;   - view fewer <#>    (2021)    Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression.                   Respirology , 26  (5)   pp. 461-468.    10.1111/resp.13988 <https://doi.org/10.1111/resp.13988>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10118088/7/Abraham_Respirology%20-%202020%20-%20Stock%20-%20Serum%20markers%20of%20pulmonary%20epithelial%20damage%20in%20systemic%20sclerosis%E2%80%90associated%20interstitial.pdf